Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma-Reference-Cited by-同舟云学术

Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma

Published:2021-11 Issue: Volume:161 Page:163-170
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Takamochi Kazuya,Hara Kieko,Hayashi Takuo,Kohsaka Shinji,Takahashi Fumiyuki,Suehara Yoshiyuki,Suzuki Kenji

Funder

Smoking Research Foundation

Juntendo University

Japan Agency for Medical Research and Development

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N Engl J Med 379(24) (2018) 2342-2350. doi: 2310.1056/NEJMoa1809697. Epub 1802018 Sep 1809625.

2. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med 373(17) (2015) 1627-1639. doi: 1610.1056/NEJMoa1507643. Epub 1502015 Sep 1507627.

3. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med 373(2) (2015) 123-135. doi: 110.1056/NEJMoa1504627. Epub 1502015 May 1504631.

4. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet 387(10030) (2016) 1837-1846. doi: 1810.1016/S0140-6736(1816)00587-00580. Epub 02016 Mar 00510.

5. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med 372(21) (2015) 2018-2028. doi: 2010.1056/NEJMoa1501824. Epub 1502015 Apr 1501819.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic profile characterization of histological micropapillary and solid components in lung adenocarcinoma: a systematic review;Journal of Laboratory and Precision Medicine;2024-07

2. PD‐L1 expression in resected lung adenocarcinoma: prevalence and prognostic significance in relation to the IASLC grading system;Histopathology;2024-01-30

3. PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center;Journal of the Egyptian National Cancer Institute;2024-01-29

4. The detection of PD‐L1 expression on liquid‐based cytology in pleural effusion of lung adenocarcinoma and its prognostic evaluation: Between paired liquid‐based cytology and cell block samples;Diagnostic Cytopathology;2024-01-23

5. Impact of RBM10 and PD-L1 expression on the prognosis of pathologic N1–N2 epidermal growth factor receptor mutant lung adenocarcinoma;Translational Lung Cancer Research;2023-10